Our Story

The link between accurately measuring glucose levels and monitoring osmotic pressure was made in the 1970s after an incident at a regional hospital in Førde, Norway. 

The son of Olav Ellingsen was admitted to the hospital with a severely swollen face and bulging eyeballs. The doctors confirmed that these symptoms came from the son’s teenage diabetes condition.

When the glucose levels became too high in his body, the cells in his body burst thus leading to these health-threatening conditions. With an injection of insulin, the symptoms disappeared. Olav Ellingsen registered a direct correlation between the osmotic pressure and glucose levels in the body and discovered that by monitoring the osmotic pressure one could read the accurate glucose levels. This discovery is the foundation of Lifecare’s solution.



  • Listed on Oslo Stock Exchange
  • Identification of method for miniaturizing pressure sensor enabling substancial device miniaturization
  • Service agreement with cantiMED UG, patentholder of nano-production method


  • In-vitro experiments confirming functionality of miniaturized pressure sensor
  • Announcement of preparations for clinical testing


  • Filing of Clinical Study Protocol
  • Lifecare recieves grant from EU Commission as part of consortium FORGETDIABETES working to develop an artificial pancreas


  • Lifecare recieves regulatory approval for first-in-human Clinical Pilot Evaluation
  • Lifecare aquires cantiMED UG (renamed Lifecare NanoBioSensors GmbH)
  • New patent granted
  • Term sheet for acquisition of the laboratory of Pfützner Science & Health Institute GmbH (later renamed to Lifecare Laboratory GmbH


  • Acquisition of Pfützner Science & Health Institute formalized and finalized
  • Successful in-vitro testing confirms functionality of miniaturized sensors with nanoscale pressure sensors, which confirms prototypes for upcoming clinical trials Start of clinical development studies, first-in-human
  • Lifecare innovations categorized among top 14% of innovations receiving funding from EU Commission.
  • Letter of intent – production location in Mainz
  • Interim data analysis: proof-of-concept in humans


  • Lifecare subsidiary unit, Lifecare Laboratory GmbH, Mainz, was ISO 9001 certified.
  • Sensor longevity: 12 weeks in-vitro
  • Lifecare signs lease agreement in Mainz
  • Lifecare launches spin-off company “Lifecare Veterinary”
  • Lifecare study confirm clinical accuracy in line with gold standard. Data from study LFC-SEN-001 confirms that the Sencell-sensor has a solid clinical accuracy: the mean average of absolute error (MARD) between Sencell and matched relative reference values was 9,6%.
  • Longevity study of Sencell Continuous Glucose Monitoring (CGM) sensor reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days).
  • The Norwegian Medicines Agency considers the Sencell sensor itself as non-medicinal product in a veterinary context and confirms that no specific regulations exist for medical devices for animals in Norway.
  • Regulatory approval from The Norwegian Food Safety Authority (NFSA) for longevity study LFC-SEN-002.
  • Lifecare Laboratory GmbH was ISO 13485 certified.
  • Preparations for manufacturing (automated production): purchase orders for software and hardware: Zeiss XB350 scanning electron microscope, and Bioscaffolder and Nanoplotter from Gesim bH.
  • Lifecare subsidiary unit, Lifecare Laboratory GmbH, Mainz, was ISO 13485 certified.
  • Preparations for manufacturing (automated production): purchase order for cleanroom
  • Board of Directors has decided to prepare for submitting application for listing of Lifecare’s shares at the main list of Oslo Stock Exchange (OSE), transferring from the current listing on Euronext Growth
  • The European Patent Office issues a new Lifecare patent and it will strengthen the company’s technology protection until 2037
  • Breakthrough – Successfully reached the target for pilot production of the Sencell sensor in Q1